~~<i id='24BCD4514B'><strike id='24BCD4514B'><tt id='24BCD4514B'><pre id='24BCD4514B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：entertainment 2025-08-23 10:36:57 - browse：24294

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： 'Brian's Song' at 50 still offers lessons about cancer for today

knowledge

hotspot

focus

hotspot

focus

AdobeHealthsystemsdrowninginmessagesfrompatientsaregraspingfornewwaystomanagethedeluge—includingchar

WSS

House passes resolution saying Israel isn't a 'racist or apartheid state'

Failure, not just success, should guide future doctors

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Sweden knocks USA out of World Cup in penalty kicks

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

focus

fashion

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Judge in Trump's classified documents case questions use of out

Drug repurposing or repositioning? The language matters

Slovenia has suffered its worst

Moonlake's readout produced a cash windfall. Risks remain

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

At least 13 dead in Texas as scorching temps continue

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Novavax promises a turnaround & Lilly roils the obesity market

Paxlovid rebound happens. Why and to whom are still a mystery

hotspot

Study: Hearing aids may slow cognitive decline in those at risk

Why you get paid to donate plasma but not blood

Judge in Trump's classified documents case questions use of out

'Brian's Song' at 50 still offers lessons about cancer for today

ER docs worry over extreme heat as a 'mass casualty event'

How CRISPR works, explained in two minutes

hotspot

focus

hotspot

focus